Bonham and colleagues developed the Racial Attributes in Clinical Evaluation (RACE) scale to assess the degree to which health professionals employ race in their clinical decision making. The scale includes eight questions, such as “I consider my patients’ race when making decisions about which medications to prescribe.”
This survey was designed to elicit responses from providers’ regarding their experiences with and perceptions about patient-generated family histories.
This semi-structured interview guide provides physicians with scenarios in which adult and pediatric patients receive unsolicited genomic results and elicits their views about the need for provider support materials, the involvement of genetic specialists in the disclosure process, concerns about liability, and other topics.
A pre- and post-test questionnaire that measures changes in the knowledge and attitudes of physicians who have been administered pharmacogenetic testing is available in the supporting information section of the linked publication in both English and Korean. The survey includes items for demographic information, clinical history, attitudes towards adverse drug reactions, experience with clinical genomics, attitudes toward and experience with pharmacogenomics, price expectations for pharmacogenomics testing, and interpretation of the value of the pharmacogenomics report.
The purpose of the MedSeq Project was to develop a process for a process for integrating information obtained from whole genome sequencing into clinical practice and to explore how physicians and their patients understand and utilize this information. The cardiologist consent provides information on the purpose of the study, study procedures, risks and possible benefits of particpating, payment, contact information for questions or concerns, and privacy protections.
This document is the study protocol of the Institutional and Professional Impact of Genomic Sequencing in Cancer Care study.
This published study protocol for the MedSeq trials includes a description of the study design; recruitment, enrollment, and sample size plan; patient exclusion/inclusion criteria; and process of interpreting WGS results and delivering them to physicians. It also includes an example of a general genome report as well as a cardiac risk report.
The Institutional and Professional Impact of Genomic Sequencing in Cancer Care examined the impact of the use of whole-exome sequencing (WES) on physicians and institutional systems at the Dana-Farber Cancer Institute (DFCI). This consent form is for clinically active oncologists involved in the care of cancer patients and members of the Cancer Genomics Evaluation Committee (CGEC), which was established to guide the incorporation of WES into cancer care.
The purpose of the MedSeq Project was to develop a process for a process for integrating information obtained from whole genome sequencing into clinical practice and to explore how physicians and their patients understand and utilize this information. This consent for primary care physicians provides information on the purpose of the study, study procedures, risks and possible benefits of particpating, payment, contact information for questions or concerns, and privacy protections.
This physician consent form was approved by the Institutional Review Board for the Baylor College of Medicine and Affiliated Hospitals for use in the Incorporation of Genomic Sequencing into Pediatric Cancer Care Study. The purpose of the study was learn how to report and use clinical exome sequencing test results for childhood cancer patients.